Having confidentially filed in late April, Karuna Therapeutics has publicly applied for an initial public offering that would raise $75m and provide exits to Nan Fung and PureTech Health.

Karuna Therapeutics, a US-based neuropsychiatric disorder drug developer backed by pharmaceutical firm PureTech Health and real estate provider Nan Fung, has filed for a $75m initial public offering. Founded in 2009, Karuna is working on treatments for neuropsychiatric conditions – mental disorders originating from the nervous system – such as schizophrenia and Alzheimer’s disease, as…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.